1. Home
  2. PRLD vs ARQ Comparison

PRLD vs ARQ Comparison

Compare PRLD & ARQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • ARQ
  • Stock Information
  • Founded
  • PRLD 2016
  • ARQ 1996
  • Country
  • PRLD United States
  • ARQ United States
  • Employees
  • PRLD N/A
  • ARQ N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • ARQ
  • Sector
  • PRLD Health Care
  • ARQ
  • Exchange
  • PRLD Nasdaq
  • ARQ NYSE
  • Market Cap
  • PRLD 280.6M
  • ARQ 249.0M
  • IPO Year
  • PRLD 2020
  • ARQ N/A
  • Fundamental
  • Price
  • PRLD $4.85
  • ARQ $5.86
  • Analyst Decision
  • PRLD Hold
  • ARQ
  • Analyst Count
  • PRLD 3
  • ARQ 0
  • Target Price
  • PRLD $5.33
  • ARQ N/A
  • AVG Volume (30 Days)
  • PRLD 242.0K
  • ARQ 160.4K
  • Earning Date
  • PRLD 10-30-2024
  • ARQ 08-12-2024
  • Dividend Yield
  • PRLD N/A
  • ARQ N/A
  • EPS Growth
  • PRLD N/A
  • ARQ N/A
  • EPS
  • PRLD N/A
  • ARQ N/A
  • Revenue
  • PRLD N/A
  • ARQ $105,078,000.00
  • Revenue This Year
  • PRLD N/A
  • ARQ $4.58
  • Revenue Next Year
  • PRLD N/A
  • ARQ $40.31
  • P/E Ratio
  • PRLD N/A
  • ARQ N/A
  • Revenue Growth
  • PRLD N/A
  • ARQ 12.87
  • 52 Week Low
  • PRLD $1.66
  • ARQ $1.50
  • 52 Week High
  • PRLD $6.80
  • ARQ $8.26
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 44.87
  • ARQ 41.13
  • Support Level
  • PRLD $4.50
  • ARQ $5.73
  • Resistance Level
  • PRLD $5.53
  • ARQ $6.84
  • Average True Range (ATR)
  • PRLD 0.45
  • ARQ 0.37
  • MACD
  • PRLD -0.09
  • ARQ -0.08
  • Stochastic Oscillator
  • PRLD 24.22
  • ARQ 9.70

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About ARQ ARQ INC

Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granular Activated Carbon, and Colloidal Carbon Product among others.

Share on Social Networks: